Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Targeting Stem Cells in Multiple Myeloma for Improved Outcomes

  • Broadcast in Health



Follow This Show

If you liked this show, you should follow CureTalks.

Multiple myeloma remains incurable despite improved remissions with novel agents. Relapse eventually occurs in the form of drug-resistant disease that carries a dismal prognosis. Relapse is dependent on stem cell functions. We are talking to Dr. William Matsui of Johns Hopkins University School of Medicine to get a better understanding of the drivers of these functions and how they may lead to novel therapies for relapsed disease.

Featured Guest: William Matsui, M.D., is Professor of Oncology, Director, Multiple Myeloma Program The Sidney Kimmel Comprehensive Cancer, Johns Hopkins University School of Medicine.

Dr. Matsui's current research is focused on normal and cancer stem cell biology. His laboratory identified tumor-initiating cells in the plasma cell malignancy multiple myeloma in 2004. He has subsequently found that these cells share several cellular processes with normal stem cells that regulate self-renewal and drug resistance. Recently, his laboratory has expanded these studies and studied human pancreatic cancers and normal hematopoiesis. Dr. Matsui he has been awarded the George Santos Research Award from the Leukemia and Lymphoma Society, the Clinician Scientist Award from Johns Hopkins University, and teaching awards from the Departments of Oncology and Medicine.

Panel: Gary Petersen, Jack Aiello, Cynthia Chmielewski, Yelak Biru, Priya Menon